EPISODE · Aug 20, 2013 · 50 MIN
The HD View with First HD
from Help 4 HD Live! · host Help 4 HD Live!
Tonight our special guests are Dr. Samuel Frank - Associate Professor of Neurology and co-Director of Neurology Resident Education at Boston University and is involved with many HSG studies and trials, and Dr. David Stamler - Chief Medical Officer at Auspex Pharmaceuticals. Tonight we will be discussing First-HD, which is is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have never taken tetrabenazine (Xenazine ®, Nitoman ®). Participants will be involved in this trial for approximately 4 months. Stay tuned and we look forward to having an awesome show tonight!
What this episode covers
Tonight our special guests are Dr. Samuel Frank - Associate Professor of Neurology and co-Director of Neurology Resident Education at Boston University and is involved with many HSG studies and trials, and Dr. David Stamler - Chief Medical Officer at Auspex Pharmaceuticals. Tonight we will be discussing First-HD, which is is a Phase III clinical research trial of an investigational drug called SD-809 Extended Release (ER) in persons who have a diagnosis of Huntington disease (HD). First-HD will be enrolling participants across North America (United States and Canada) who have been diagnosed with HD and who have never taken tetrabenazine (Xenazine ®, Nitoman ®). Participants will be involved in this trial for approximately 4 months. Stay tuned and we look forward to having an awesome show tonight!
NOW PLAYING
The HD View with First HD
No transcript for this episode yet
Similar Episodes
Mar 19, 2026 ·34m
Feb 24, 2026 ·13m
Feb 18, 2026 ·11m
Feb 17, 2026 ·9m
Feb 11, 2026 ·45m
Feb 11, 2026 ·7m